SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-19-000008
Filing Date
2019-08-07
Accepted
2019-08-07 16:22:27
Documents
57
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20190630x10q.htm 10-Q 1335687
2 EXHIBIT 31.1 allo-20190630xex311.htm EX-31.1 11053
3 EXHIBIT 31.2 allo-20190630xex312.htm EX-31.2 11080
4 EXHIBIT 32.1 allo-20190630xex321.htm EX-32.1 9384
  Complete submission text file 0001737287-19-000008.txt   5417529

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT allo-20190630.xml EX-101.INS 1001857
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20190630.xsd EX-101.SCH 42303
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20190630_cal.xml EX-101.CAL 61732
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20190630_def.xml EX-101.DEF 193881
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20190630_lab.xml EX-101.LAB 573594
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20190630_pre.xml EX-101.PRE 325313
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 191005817
SIC: 2836 Biological Products, (No Diagnostic Substances)